Web Analytics

3 Latest Announced Rounds

  • $1,300,000
    Pre-Seed

    5 Investors

    Marketing Services
    Nov 19th, 2025
  • $17,500,000
    Seed

    5 Investors

    Wellness and Fitness Services
    Nov 19th, 2025
  • $4,200,000
    Seed

    2 Investors

    Software Development
    Nov 19th, 2025
$1,146.75M Raised in 59 Funding Rounds in the past 7 Days - View All

Funding Round Profile

Infinity Bio, Inc.

start up
United States - Baltimore, Maryland
  • 19/06/2025
  • Series A
  • $8,000,000

Infinity Bio is a technology company that provides detailed insights into the immune system using its proprietary antibody profiling platform. The company’s core technology comprehensively measures the antibody reactome, revealing the targets of individual immune responses against all known human viruses, human proteins (autoimmunity), and allergen proteins. Infinity's assay, MIPSA, was developed at Johns Hopkins University in Ben Larman's Lab of Precision Immunology. It builds off decades of work in the fields of genomics, proteomics, immunology, and bioinformatics. Our assay was engineered to enable best-in-class turnaround times and cost. With a team of experienced professionals and a state-of-the-art facility, we are poised to make a significant impact to research and for our customers.


Related People

Joy M. NassifFounder

Joy M. Nassif United States - Mendham, New Jersey

N/A